Plasminogen Activator Inhibitor-1 Levels and Activity Decrease After Intervention in Patients with Critical Limb Ischaemia

被引:5
作者
Bjorck, M. [1 ]
Eriksson, M. Lepkowska [2 ]
Bylock, A. [2 ]
Steuer, J. [1 ]
Wanhainen, A. [1 ]
Carlsson, B. C. L. [2 ]
Bock, D. [2 ,3 ]
Kragsterman, B. [1 ]
机构
[1] Uppsala Univ, Vasc Surg Sect, Dept Surg Sci, SE-75185 Uppsala, Sweden
[2] AstraZeneca Res & Dev, Molndal, Sweden
[3] AZ R&D, Stat Dept, Molndal, Sweden
关键词
Critical limb ischaemia (CLI); Inflammation; Peripheral arterial occlusive disease (PAOD); Plasminogen activator inhibitor-1 (PAI-1); Thrombosis; Treatment; RAT MODEL; CLOPIDOGREL; ASPIRIN;
D O I
10.1016/j.ejvs.2013.05.011
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective/background: Patients with peripheral arterial occlusive disease (PAOD), in particular critical limb ischaemia (CLI), carry a high risk of thrombotic events. We hypothesised that patients undergoing conservative, endovascular, or open surgical treatment for CLI have increased levels of plasminogen activator inhibitor-1 (PAI-1), leading to a prothrombotic state. The objective was to determine levels of PAI-1 in patients with acute or chronic PAOD/CLI. Methods: Thirty-two patients with a median age of 74 (49-90) years were included. Three underwent thrombolysis for acute limb-threatening ischaemia. Twenty-six patients with chronic ischaemia received endovascular (n = 20) or open (n = 6) surgical treatment. Three were treated conservatively. Biomarkers and ankle brachial index (ABI) were measured before and up to 1 month after intervention. Patency was studied with repeated duplex ultrasound. Results: Ankle pressure and ABI improved after intervention (p < .001). C-reactive protein (CRP) increased from a median of 7.90 mg/L at baseline to 31.5 on day 1 (p < .001), 28.0 on day 6 (p < .001), and returned to baseline levels on day 30. PAI-1 antigen and activity decreased from day 6 and onwards post-intervention compared with baseline (p < .05). A great individual variability in PAI-1 antigen and activity was observed. Although most actively treated patients had normal PAI-1 activity, 11/29 (38%) were above that level of normality at baseline, 10/24 (42%) on day 1, 3/23 (13%) on day 6, and 5/27 (19%) on day 30 after intervention. Conclusion: Endovascular and open surgical treatment resulted in improved ankle pressure and ABI. The intervention was followed by a transient increase in CRP and a sustained reduction in PAI-1 levels and activity. (C) 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:214 / 222
页数:9
相关论文
共 16 条
[1]  
[Anonymous], 1994, BMJ-BRIT MED J, V308, P159
[2]   Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial [J].
Belch, Jill J. F. ;
Dormandy, John .
JOURNAL OF VASCULAR SURGERY, 2010, 52 (04) :825-833
[3]   Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial) [J].
Cannon, CP .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (07) :760-+
[4]   Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes [J].
Festa, A ;
Williams, K ;
Tracy, RP ;
Wagenknecht, LE ;
Haffner, SM .
CIRCULATION, 2006, 113 (14) :1753-1759
[5]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[6]   Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis [J].
Hennan, J. K. ;
Morgan, G. A. ;
Swillo, R. E. ;
Antrilli, T. M. ;
Mugford, C. ;
Vlasuk, G. P. ;
Gardell, S. J. ;
Crandall, D. L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1558-1564
[7]   ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic): Executive summary [J].
Hirsch, AT ;
Haskal, ZJ ;
Hertzer, NR ;
Bakal, CW ;
Creager, MA ;
Halperin, JL ;
Hiratzka, LF ;
Murphy, WRC ;
Olin, JW ;
Puschett, JB ;
Rosenfield, KA ;
Sacks, D ;
Stanley, JC ;
Taylor, LM ;
White, CJ ;
White, J ;
White, RA ;
Antman, EM ;
Smith, SC ;
Adams, CD ;
Anderson, JL ;
Faxon, DP ;
Fuster, V ;
Gibbons, RJ ;
Halperin, JL ;
Hiratzka, LF ;
Hunt, SA ;
Jacobs, AK ;
Nishimura, R ;
Ornato, JP ;
Page, RL ;
Riegel, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (06) :1239-1312
[8]   Acrocyanosis: The Flying Dutchman (vol 16, pg 288, 2011) [J].
Kurklinsky, Andrew K. ;
Miller, Virginia M. ;
Rooke, Thom W. .
VASCULAR MEDICINE, 2011, 16 (05) :409-409
[9]   A Detailed Cardiovascular Characterization of Obesity Without the Metabolic Syndrome [J].
Lind, Lars ;
Siegbahn, Agneta ;
Ingelsson, Erik ;
Sundstrom, Johan ;
Arnlov, Johan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (08) :E27-U24
[10]   Adipose Tissue Macrophages: A Piece of the PAI of Metabolic Syndrome [J].
Lumeng, Carey N. .
SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (20)